The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

May 09, 2024

Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.

May 09, 2024

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

May 02, 2024

Núria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.

May 02, 2024

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

May 02, 2024

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

May 01, 2024

Naval G. Daver, MD, discusses the future of targeted therapy development for patients with acute myeloid leukemia.

May 01, 2024

Elias Jabbour, MD, discusses outcomes from the phase 3 PhALLCON trial in patients with Ph-positive acute lymphoblastic leukemia.

May 01, 2024

Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.

April 30, 2024

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

April 29, 2024

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.

April 26, 2024

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

April 24, 2024

James Ignatz-Hoover, MD, PhD, discusses the implications of utilizing blinatumomab to treat acute lymphoblastic leukemia.

April 23, 2024

Eric K. Singhe, MD, of The University of Texas MD Anderson Cancer Center, discusses the journey of non–smell cell lung cancer treatment through mentorship, advocacy, and more.

April 23, 2024

Samer A. Srour, MB ChB, MS, discusses the investigation of the allogeneic CAR T-cell therapy CTX131 in advanced clear cell renal cell carcinoma.

April 22, 2024

Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.

April 19, 2024

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.

April 18, 2024

Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.

April 18, 2024

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

April 18, 2024

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

April 18, 2024

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.